Changing Landscape for Pharmaceutical Development and Manufacturing

Wednesday
April 4, 2018
3:00 pm
Wu and Chen Auditorium
Levine Hall

RECEPTION TO FOLLOW

Paul McKenzie
Executive Vice President
Pharmaceutical Operations and Technology
Biogen

Abstract
As the pipelines of innovators continue to diversify across modalities, every company will face the challenge of both building needed capabilities for all modalities while maintaining their existing capacities and capabilities dedicated to any particular modality completely consumed by the current portfolio. In addition to this diversification, the productivity of more mature modality platforms is increasing significantly, driving current facilities to be under-utilized or in need of redesign. This inflection point will create the need for different partnership models amongst innovator companies and between innovator companies and contract manufacturing and laboratory organizations. Since owning everything will be a significant burden, the onus will be on each company to clearly delineate what it can manage and what it can access through these partnerships. In this talk we highlight progress of Biogen’s manufacturing platforms for anti-sense oligo nucleotides and for monoclonal antibodies given these realities.

Bio
Paul McKenzie, Ph.D., is the Executive Vice President of Pharmaceutical Operations & Technology at Biogen and has served on the Executive Committee since July 2016. Dr. McKenzie is responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering. He also oversees construction and operation of Biogen’s advanced biologics manufacturing facility in Solothurn, Switzerland. Dr. McKenzie serves on board of directors for Samsung Bioepis.

He joined the company in February 2016, as Senior Vice President for Global Biologics Manufacturing & Technical Operations. Prior to joining Biogen, Dr. McKenzie was most recently Vice President of R&D for Johnson & Johnson’s Ethicon business. During his tenure at J&J, he led the manufacturing and technical operations team, responsible for internal and external manufacturing of Janssen’s pharmaceutical portfolio as well as Global Development for Janssen R&D, helping to manage pipeline activities from discovery through clinical development and commercialization. He also held various R&D and manufacturing positions at Bristol-Myers Squibb and Merck.

Dr. McKenzie holds a B.S. in Chemical Engineering from the University of Pennsylvania and a Ph.D. in Chemical Engineering from Carnegie Mellon University. He has served on numerous professional and academic boards, most recently Board of Trustees on the Illinois Institute of Technology and the Society for Biological Engineering.